Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma

D Danny Luan (1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) O Ori Ben Valid (3Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel) O Ofrat Beyar-Katz (5Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel) T Tobias Tix (7Department of Medicine III, Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany) N Noa Golan Accav (3Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel) M Mohammad Alhomoud (1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) A Abraham Avigdor (3Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel) V Veit L. Bücklein (7Department of Medicine III, Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany) L Limor Cohen P Parastoo B. Dahi (1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) S Sigrun Einarsdottir (1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) J Julia Elimelech (5Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel) S Silvia Escribano-Serrat (1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) L Lorenzo Falchi (Memorial Sloan Kettering Cancer Center, New York) T Teng Fei (College of Life and Health Sciences, Northeastern University) S Sergio Giralt (1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) M Marina Gomez-Llobell (1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) A Andre Goy (14Division of Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, NJ) N Nurit Horesh S Sapir Israeli (1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) L Linus Kruk (7Department of Medicine III, Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany) L Lori Leslie (14Division of Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, NJ) J Jennifer K. Lue (2Department of Medicine, Weill Cornell Medical College, New York, NY) R Ronit Marcus (3Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel) A Arnon Nagler (3Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel) M M. Lia Palomba (5Memorial Sloan Kettering Cancer Center, New York, NY) J Jae H. Park S Sandeep Raj (1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) S Siddhartha Reddy (14Division of Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, NJ) J Jason Romancik (14Division of Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, NJ) E Efrat Rosenbaum (15Hematology Division, Bone Marrow Transplant Unit, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel) G Gilles Salles (41Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY) M Michael Scordo (Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York) G Gunjan L. Shah (Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York) A Avichai Shimoni (3Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel) M Michael von Bergwelt-Baildon (Ludwig Maximilian University Hospital, Munich, Germany) M Miguel-Angel Perales (1Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY) M Marion Subklewe (Ludwig Maximilian University Hospital, Munich, Germany) U Uri Greenbaum (8Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel) A Andrew Ip (14Division of Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, NJ) R Ron Ram (15Hematology Division, Bone Marrow Transplant Unit, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel) K Kai Rejeski (Memorial Sloan Kettering Cancer Center, New York, New York, United States) R Roni Shouval (1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY)

Abstract

Abstract Circadian rhythms orchestrate immune activation and effector function, yet whether within-day timing influences chimeric antigen receptor (CAR) T-cell therapy outcomes remains unknown. We conducted an international, multicenter retrospective study of 1052 adults with relapsed or refractory large B-cell lymphoma treated with CD19-directed CAR T-cell therapy across 7 centers (2017-2025). The median infusion time was 11:48 am (interquartile range, 11:06 am to 12:45 pm). Each hour later in infusion time was associated with an increased risk of progression, relapse, or death (hazard ratio, 1.11; 95% confidence interval, 1.03-1.20; P = .004) after adjustment for center, product, and key clinical variables. One-year progression-free survival (PFS) was 51.4% for early (before 12:00 noon) infusion vs 35.2% for late (at or after 12:00 noon) infusion, whereas overall survival was similar between groups. The PFS benefit was driven by lower relapse and higher complete response rates in the early infusion group. Although no differences were observed in immune toxicities, late infusion correlated with higher peak inflammatory markers and reduced day 7 CAR T-cell expansion. Together, these findings suggest that the timing of CAR T-cell infusion may influence therapeutic efficacy and support prospective evaluation of circadian-informed delivery strategies.

Article Details

Journal Blood
Volume / Issue Vol. 147, Issue 12
Published March 19, 2026
Pages 1315-1322
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (43)

D

Danny Luan

1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

O

Ori Ben Valid

3Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel

O

Ofrat Beyar-Katz

5Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel

T

Tobias Tix

7Department of Medicine III, Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany

N

Noa Golan Accav

3Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel

M

Mohammad Alhomoud

1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

A

Abraham Avigdor

3Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel

V

Veit L. Bücklein

7Department of Medicine III, Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany

L

Limor Cohen

P

Parastoo B. Dahi

1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

S

Sigrun Einarsdottir

1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

J

Julia Elimelech

5Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel

S

Silvia Escribano-Serrat

1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

L

Lorenzo Falchi

Memorial Sloan Kettering Cancer Center, New York

T

Teng Fei

College of Life and Health Sciences, Northeastern University

S

Sergio Giralt

1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

M

Marina Gomez-Llobell

1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

A

Andre Goy

14Division of Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, NJ

N

Nurit Horesh

S

Sapir Israeli

1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

L

Linus Kruk

7Department of Medicine III, Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany

L

Lori Leslie

14Division of Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, NJ

J

Jennifer K. Lue

2Department of Medicine, Weill Cornell Medical College, New York, NY

R

Ronit Marcus

3Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel

A

Arnon Nagler

3Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel

M

M. Lia Palomba

5Memorial Sloan Kettering Cancer Center, New York, NY

J

Jae H. Park

S

Sandeep Raj

1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

S

Siddhartha Reddy

14Division of Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, NJ

J

Jason Romancik

14Division of Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, NJ

E

Efrat Rosenbaum

15Hematology Division, Bone Marrow Transplant Unit, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel

G

Gilles Salles

41Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY

M

Michael Scordo

Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York

G

Gunjan L. Shah

Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York

A

Avichai Shimoni

3Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel

M

Michael von Bergwelt-Baildon

Ludwig Maximilian University Hospital, Munich, Germany

M

Miguel-Angel Perales

1Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY

M

Marion Subklewe

Ludwig Maximilian University Hospital, Munich, Germany

U

Uri Greenbaum

8Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel

A

Andrew Ip

14Division of Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, NJ

R

Ron Ram

15Hematology Division, Bone Marrow Transplant Unit, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel

K

Kai Rejeski

Memorial Sloan Kettering Cancer Center, New York, New York, United States

R

Roni Shouval

1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY